Chilton Investment Company’s Adaptive Biotechnologies ADPT Stock Holding History

Chilton Investment Company’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,392	Closed	-$874K	–	159
2021 Q2	$874K	Sell	21,392 -268,635	-93%	-$10.4M	0.02%	93
2021 Q1	$11.7M	Sell	290,027 -27,727	-9%	-$1.5M	0.32%	39
2020 Q4	$18.8M	Buy	317,754 +128,986	+68%	+$6.65M	0.54%	31
2020 Q3	$9.18M	Buy	188,768 +145,376	+335%	+$6.11M	0.27%	39
2020 Q2	$2.1M	Buy	+43,392	New	+$1.58M	0.07%	75

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Chilton Investment Company's ADPT Position: Q3 2021 in Review

Chilton Investment Company sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 21,392 shares — an estimated $874K sold.

Chilton Investment Company first reported a position in ADPT in Q2 2020 and held it in 5 quarters. The position peaked at $18.8M in Q4 2020. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

Chilton Investment Company reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
Chilton Investment Company sold 21,392 Adaptive Biotechnologies shares in Q3 2021, an estimated $874K.
Chilton Investment Company first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 5 quarters.
Chilton Investment Company's Adaptive Biotechnologies position peaked at $18.8M in Q4 2020.
219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Chilton Investment Company's 13F filing for Q3 2021, filed 5 Nov 2021.